
Gentian Diagnostics Investor Relations Material
Latest events

Q2 2025
Gentian Diagnostics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Gentian Diagnostics
Access all reports
Gentian Diagnostics ASA is a Norwegian company that specializes in the development and production of in-vitro diagnostic (IVD) reagents. The company’s focus is on creating biochemical reagents for use in clinical chemistry analyzers, particularly utilizing Particle-Enhanced Turbidimetric Immunoassays (PETIA). These assays enable faster, automated testing for various medical conditions, improving operational efficiency for clinical labs. Gentian’s products target key areas such as infections, inflammation, kidney disease, cardiac conditions, and veterinary medicine. Gentian Diagnostics is headquartered in Moss, Norway, and its shares are listed on the Oslo Stock Exchange.
Key slides for Gentian Diagnostics


Q4 2024
Gentian Diagnostics


Q2 2025
Gentian Diagnostics
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
GENT
Country
🇳🇴 Norway